All News

10 July 2008

Recruitment Completed in Ofatumumab CLL Front Line StudyAntibodies

9 July 2008

Cerimon Pharmaceuticals Initiates Phase II Study to Evaluate Simulect(R) (basiliximab) for Noninfectious UveitisAntibodies

9 July 2008

Merck Begins Erbitux Phase III Clinical Study in Gastric CancerAntibodies

9 July 2008

Boehringer Ingelheim Gains Access to Additional MorphoSys TechnologyAntibodies

8 July 2008

Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with Daiichi SankyoAntibodies

7 July 2008

Phase 2 Study Of IMC-A12 for Advanced Soft Tissue Sarcoma Opens for Patient EnrollmentAntibodies

7 July 2008

ImmunoGen, Inc. Announces Start of IMGN388 Clinical TestingAntibodies

3 July 2008

Phase III ARISER study with RENCAREX(R): patient recruitment successfully completedAntibodies

2 July 2008

Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast CancerAntibodies

1 July 2008

UCB’s Cimzia(R) filed with EMEA for treatment of rheumatoid arthritisAntibodies

30 June 2008

Takeda Submitted a New Drug Application for Anti-Cancer Agent, panitumumab (recombinant)Antibodies

29 June 2008

Centocor, Inc. Submits Application to FDA Requesting Approval of Golimumab for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing SpondylitisAntibodies

29 June 2008

New Data Show Preemptive Treatment May Significantly Reduce Skin Toxicities in Patients Receiving Vectibix(R) (Panitumumab)Antibodies

25 June 2008

Genmab Initiates Study of Zalutumumab with Radiotherapy in Head and Neck CancerAntibodies

25 June 2008

CuraGen Announces Initiation of Phase II Trial of CR011-vcMMAE in Patients with Advanced Breast CancerAntibodies

25 June 2008

IMC-A12 Plus Temsirolimus Clinical Trial for Advanced Cancer Opens for Patient EnrollmentAntibodies

24 June 2008

Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmune DiseasesAntibodies

19 June 2008

Merck Applies to Extend Use of Erbitux for First-Line Head and Neck Cancer in EuropeAntibodies

19 June 2008

Amgen and Wyeth Statement on Outcome of Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) MeetingAntibodies

18 June 2008

Biotie’s VAP-1 Antibody Program to Proceed to Clinical Studies in Rheumatoid Arthritis and Psoriasis PatientsAntibodies

18 June 2008

FDA Advisory Committee Unanimously Recommends Approval of Ustekinumab for Treatment of Moderate to Severe Plaque PsoriasisAntibodies

18 June 2008

ThromboGenics and BioInvent announce a strategic alliance with Roche for TB-403, a novel anti-cancer antibodyAntibodies

17 June 2008

Trubion Pharmaceuticals Announces Presentation of Positive TRU-015 and SBI-087 Data at the 2008 Annual European Congress of Rheumatology MeetingAntibodies

17 June 2008

Elan and Wyeth Announce Encouraging Top-line Results from Phase 2 Clinical Trial of Bapineuzumab for Alzheimer’s DiseaseAntibodies

16 June 2008

Romiplostim Data Show Potential Long-Term Efficacy and Safety in Adults with Chronic ITPAntibodies

16 June 2008

OncoMed Pharmaceuticals Extends License Agreement for Use of MorphoSys’s Core TechnologyAntibodies

15 June 2008

HUMIRA(R) (adalimumab) Data Show That Treating Early Rheumatoid Arthritis with Combination Treatment Resulted in Cost Savings From Improved Work ProductivityAntibodies

15 June 2008

Data Show that Abbott’s HUMIRA(R) (adalimumab) Reduced the Signs and Symptoms of Ankylosing Spondylitis Up to Three YearsAntibodies

15 June 2008

New Long-Term HUMIRA(R) (adalimumab) Data Show Up to Seven-Year Efficacy with Combination Treatment for Rheumatoid ArthritisAntibodies

15 June 2008

Data from Phase II Exploratory Study Suggest That ORENCIA(R) (abatacept) May Delay Development of Rheumatoid Arthritis in Adults with Undifferentiated Inflammatory ArthritisAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Cadherin 17: A target opportunity to develop effector-enhanced drug modalities

B7-H3-Targeted Immunotherapy Candidates Pipeline Review

2FOR1 Report Package: Vectorized Antibody and Prodrug Antibody & Cytokine landscape analysis report package with 50% discount

Aflibercept (Eylea) Biosimilars Pipeline Review

c-Met-Targeted Antibody Therapy Pipeline Review

CD47 and SIRP-alpha Targeted Immunotherapy Pipeline Review

EpCAM-Targeted Antibodies Pipeline Review

Folate Receptor alpha (FRα) Targeted Therapy Pipeline Review

CD40 Agonists & CD40/L Antagonists Pipeline Review

Blockbuster Biologics 2019: Sales of Recombinant Therapeutic Antibodies & Proteins